Molica S, et al. - This review concentrated on the efficiency of ibrutinib in relapsed/refractory (R/R) individuals and in the frontline setting by taking into consideration the fact that the therapeutic landscape of chronic lymphocytic leukemia (CLL) is quickly evolving under the pressure of recent progress in the understanding of the biology of this disease. CLL is mostly a disease of the old, so if we have therapies that give durable control of the disease for many years, like ibrutinib, a large number of people will not stick to CLL. Thus, for individuals with low-risk disease, therapy with single-agent ibrutinib should be part of a sequential strategy, particularly in elderly people (aged >70 years) with a greater burden of comorbidities.